PARP1 and breast cancer: The one result was targeting cytoplasmic immunoreactivity while another was targeting nuclear immunoreactivity, which finally misled to the wrong conclusion that high PARP expression is associated with better survival in locally advanced breast cancers and poor survival in early breast cancers.